Visium Asset Management

Visium Asset Management

Visium Asset Management was founded in 2005 by Jacob Gottlieb, a former portfolio manager at Sanford C. Bernstein and a trained physician. The firm operated as a multi-strategy hedge fund with a core focus on long/short equity and event-driven investments. Gottlieb's medical background informed a deep specialization in healthcare and biotech positions, where Visium established a strong research edge. The firm's investment strategy covered public equities across sectors including healthcare, technology, consumer, energy, and financials. Visium was known for fundamental, bottom-up research and concentrated portfolios. At its peak, the firm managed roughly $8B in assets, with a mix of long/short and event-driven strategies that included positions in companies like Pfizer, Merck, and others in the healthcare space. The firm invested globally but had a strong US-centric bias. Visium's team grew to over 100 professionals by the mid-2010s, with offices in New York, London, and San Francisco. In 2016, the firm became entangled in a high-profile insider-trading investigation by US prosecutors. The probe led to the conviction of a former portfolio manager, and Visium agreed to pay $10M in penalties and return ill-gotten gains. Gottlieb announced the closure of the firm's London office in 2016 and the wind-down of its funds by 2019. The structural differentiator for Visium was its combination of a physician-founder's domain expertise in healthcare with a traditional hedge fund model. This gave it a credible research advantage in a sector where fundamental analysis is critical. However, the insider-trading scandal ultimately led to the firm's dissolution, highlighting the risks of aggressive information sourcing in specialized niches.